SCHEMBL10134405

SCHEMBL10134405

CCCN1CCN(c2ccc(Nc3ccc(-c4ccc(C(N)=O)cc4)n4ccnc34)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPKAPK5 Q8IW41 9/20 0.56
JAK2 O60674 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
TTK P33981 1/20 0.41
TP53BP1 Q12888 1/20 0.40
MT-CO2 P00403 1/20 0.39
CHEK1 O14757 1/20 0.39
FLT3 P36888 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134452 0.93 MAPKAPK5 (0.58) MAPKAPK5JAK2MEN1ALDH1A1HTT
SCHEMBL13922282 0.92 MAPKAPK5 (0.47) MAPKAPK5JAK2MT-CO2FLT3
SCHEMBL10134411 0.91 MAPKAPK5 (0.54) MAPKAPK5JAK2MEN1ALDH1A1HTT
SCHEMBL1685153 0.90 MAPKAPK5 (0.61) MAPKAPK5JAK2CHEK1
SCHEMBL10134441 0.87 MAPKAPK5 (0.56) MAPKAPK5JAK2MEN1ALDH1A1HTT
SCHEMBL1685200 0.86 MAPKAPK5 (0.58) MAPKAPK5JAK2TTKTP53BP1
SCHEMBL1685165 0.86 MAPKAPK5 (0.75) MAPKAPK5JAK2FLT3HDAC1
SCHEMBL13922456 0.85 MAPKAPK5 (0.48) MAPKAPK5CHEK1FLT3HDAC1
SCHEMBL13922470 0.85 MAPKAPK5 (0.39) MAPKAPK5MT-CO2
SCHEMBL1046936 0.84 MAPKAPK5 (0.44) MAPKAPK5JAK2MEN1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-7951818-B2 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2011-05-31 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2009-02-19 US disclosed
WO-2008065199-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885JAK2 1510/4885MEN1 4507/4885
US-20090048245-A1 Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases COL2A1, MMP1, COL1A1 MAPKAPK5 19/4885JAK2 1510/4885MEN1 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.